Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05166499 · ClinicalTrials.gov registry record · NA

HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis

A NA study of Cirrhosis, Liver, sponsored by The Cleveland Clinic.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT05166499 is a NA study of Cirrhosis, Liver that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 24 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05166499, a NA study of Cirrhosis, Liver, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation. No proven treatments exist for the prevention or reversal of sarcopenia in cirrhosis, primarily because the mechanisms responsible for this are unknown. Based on compelling preliminary studies and those of the co investigator, investigators hypothesize that the mechanism of reduced skeletal muscle mass in cirrhosis is due to a myostatin mediated impaired mTOR (mechanistic target of rapamycin) signaling resulting in reduced protein synthesis and increased autophagy. Investigators further postulate that leucine, a direct stimulant of mTOR, will reverse the impaired mTOR phosphorylation in the skeletal muscle of cirrhotics. The consequent increase in protein synthesis reduced autophagy will result in an increase in skeletal muscle mass. Investigators will test these hypotheses by quantifying the response to acute and long term (3 month) administration of hydroxymethyl butyrate (HMB) enriched essential amino acid compared with an isonitrogenous isocaloric non-essential balanced amino acid mixture (does not stimulate protein synthesis) in cirrhotic patients. Fractional protein synthesis rate (FSR) in skeletal muscle, responses of the molecular regulatory pathways of skeletal muscle protein synthesis, and autophagy flux will be quantified in the acute and long term protocols. Tracer studies using L-\[D5\]-phenylalanine (Phe) as a primed constant infusion (prime 2µmol.kg-1.hr-1; constant 0.05 µmol.kg-1.hr-1) with and L \[ring-D2\] tyrosine, forearm plethysmography, and sequential skeletal muscle biopsies (total of 3 per study subject) will be used to quantify these outcomes. Anthropometric, clinical and body composition measures will be additional outcome measures for the long term intervention. Expression of regulatory signaling proteins, myostatin, IGF-1 (insulin like grow

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Hydroxy Methyl Butyrate
  • DIETARY_SUPPLEMENT Balanced Amino Acids

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-11-30
Est. Completion 2026-12-30
Phase NA

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT05166499

The ClinicalTrials.gov registry entry for NCT05166499 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (90% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cirrhosis, Liver appearing as the primary indexed condition, and to 2 interventions - of which Hydroxy Methyl Butyrate is the first listed.

NCT05166499 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05166499 about?

NCT05166499 is a clinical study titled "HMB Enriched Amino Acids to Reverse Muscle Loss in Cirrhosis". Loss of skeletal muscle mass or sarcopenia is the most common and potentially reversible complication in cirrhosis that increases morbidity and mortality before, during and after liver transplantation. No proven treatments exist for the prevention or reversal of sarcopenia in cirrhosis, primarily be...

What is the current status of trial NCT05166499?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2021-11-30. Estimated completion is 2026-12-30.

What conditions does trial NCT05166499 study?

This clinical trial studies the following conditions: Cirrhosis, Liver.

What interventions are being tested in trial NCT05166499?

The interventions under investigation include: Hydroxy Methyl Butyrate (DIETARY_SUPPLEMENT), Balanced Amino Acids (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05166499?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05166499 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cirrhosis, Liver

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.